Paroxetine: current status in psychiatry

  title={Paroxetine: current status in psychiatry},
  author={Chi-Un Pae and Ashwin A. Patkar},
  journal={Expert Review of Neurotherapeutics},
  pages={107 - 120}
  • C. Pae, A. Patkar
  • Published 1 February 2007
  • Psychology, Medicine
  • Expert Review of Neurotherapeutics
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) with antidepressant and anxiolytic properties. It is commercially available in both an immediate-release (paroxetine) and a controlled-release formulation (paroxetine CR). The latter product was developed to improve gastrointestinal tolerability. Paroxetine is the most potent inhibitor of the reuptake of serotonin among the available SSRIs. It has approved indications for the treatment of major depression, obsessive–compulsive… 
Paroxetine: safety and tolerability issues
Whether the tolerability profile of paroxetine differs substantially from other new antidepressants (including other SSRIs) needs to be determined in adequately powered well-designed randomised controlled comparative clinical trials.
Extended-release formulation of venlafaxine in the treatment of post-traumatic stress disorder
A review of the potential role of venlafaxine XR in the treatment of PTSD, based on currently available evidence, finds that it has not been extensively studied for PTSD, compared with other anxiety disorders.
Paroxetine—Overview of the Molecular Mechanisms of Action
The purpose of this review is to describe the interaction of paroxetine with several molecular targets in various points of view including the basic chemical and pharmaceutical properties.
A comparative review of escitalopram, paroxetine, and sertraline: are they all alike?
Overall, as an allosteric serotonin reuptake inhibitor that is somewhat different from classical SSRIs, escitalopram is the first choice judged by combined efficacy and tolerability, and nonclinical data have offered possible mechanisms through which escITALopram could be more efficacious.
Review: Problems associated with long-term treatment with selective serotonin reuptake inhibitors
Although the selective serotonin reuptake inhibitors (SSRIs), which are now widely used as a first-line treatment for depression and many other psychiatric conditions, are generally well tolerated,
Short-term serotonergic but not noradrenergic antidepressant administration reduces attentional vigilance to threat in healthy volunteers.
Citalopram reduced attentional vigilance towards fearful faces but did not affect the interpretation of ambiguous homographs as threatening, which supports a growing literature suggesting that an important mechanism through which pharmacological agents may exert their effects on mood is by reversing the cognitive biases that characterize the disorders that they treat.
Combined prolonged exposure therapy and paroxetine for PTSD related to the World Trade Center attack: a randomized controlled trial.
Initial treatment with paroxetine plus prolonged exposure was more efficacious than prolonged exposure plus placebo for PTSD related to the World Trade Center attack.
Effect of comedication of bupropion and other antidepressants on body mass index
This study reports an adverse weight gain on co-medication of escitalopram and bupropion, which warrants further validation studies, as considering co- medication effects of antidepressants on weight is important to design robust depression treatment plans.
Antidepressant treatment of premature ejaculation: discontinuation rates and prevalence of side effects for dapoxetine and paroxetine in a naturalistic setting
Investigation of prevalence of and reasons for selective serotonin reuptake inhibitor (SSRI) discontinuation and compare the two most common SSRIs used in premature ejaculation (PE) treatment, in naturalistic settings confirmed paroxetine was more effective and better tolerated than dapoxetines.


Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders.
Long term data suggest that paroxetine is effective and well tolerated, and suitable as first-line therapy for depression, and also appears to be a useful alternative to other available agents for the treatment of patients with OCD or panic disorder.
Paroxetine: an update of its use in psychiatric disorders in adults.
Given the high degree of psychiatric comorbidity of depression and anxiety, paroxetine is an important first-line option for the treatment of major depressive disorder, OCD, panic disorder, social anxiety disorder, GAD and PTSD.
Paroxetine Controlled Release
In well designed placebo-controlled trials in patients with major depressive disorder, social anxiety disorder or premenstrual dysphoric disorder, paroxetine CR was consistently superior to placebo with regards to primary endpoints.
Efficacy of controlled-release paroxetine in the treatment of late-life depression.
Paroxetine CR and parxetine IR are effective and well tolerated treatments for major depressive disorder in elderly patients, including those with chronic depression.
Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder.
BACKGROUND Paroxetine has demonstrated efficacy in depression and anxiety disorders, including generalized anxiety disorder (GAD). This 32-week study evaluated the maintained efficacy and safety of
Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression.
Paroxetine CR is an effective and well-tolerated antidepressant exhibiting symptomatic improvement as early as week 1 and its favorable adverse event profile suggests a benefit for therapeutic outcome with paroxETine CR.
Selective serotonin reuptake inhibitors in the treatment of affective disorders—III. Tolerability, safety and pharmacoeconomics
Knowledge of the differences that exist among the SSRIs in respect of tolerability and safety will aid physicians in the selection of the most beneficial treatment strategy for their patients, as well as translating into significantly different economic outcomes within the group.
Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression.
It is indicated that enhancing serotonergic function with an SSRI may reduce suicidal behavior in a subgroup of patients who have attempted suicide more than once but who do not suffer from major depression.
Paroxetine: a review of its pharmacology, pharmacokinetics and utility in the treatment of a variety of psychiatric disorders.
  • W. Heydorn
  • Medicine, Psychology
    Expert opinion on investigational drugs
  • 1999
The efficacy seen in short-term studies with paroxetine in the treatment of depression is maintained when the drug is given chronically, and the compound shows efficacy superior to placebo, and similar to that obtained with standard tricyclic or tetracyclic agents.
Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
The primary efficacy analysis revealed that both the 12.5-mg and the 25-mg paroxetine CR treatment groups were associated with significant therapeutic effects, and quality of life was assessed by the change from baseline in total score of the short form of the Quality of Life Enjoyment and Satisfaction Questionnaire.